Caralee Schaefer, PhD
Caralee is a translational research scientist with over 20 years of pharmacology and drug development experience, with a particular focus on inflammation, autoimmunity, and fibrosis research. She has extensive in vivo proof-of-concept and target validation experience, including the establishment of robust and reproducible animal models for evaluating novel therapies for multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, fibrotic diseases, and cancer. She has been a board member of the Inflammation Research Association since 2010, and in 2012 was elected an officer (currently the President).
Caralee received her BA at Adrian College in Biology, and her PhD at Wayne State University in Immunology. After a post-doctoral fellowship at Parke-Davis/Warner Lambert, she joined Berlex Biosciences (1999-2007) and was responsible for leading a team of pharmacologists that evaluated novel therapeutics for inflammation, multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Caralee then joined Intermune (2008-2015), where she developed in vivo screening platforms for evaluating novel therapeutics for pulmonary, hepatic, dermal, and renal fibrosis. In 2015, Caralee joined Blade Therapeutics as the Senior Director of Pharmacology responsible for the preclinical development of novel antifibrotic compounds. She coordinated a diverse team of scientists to accomplish in vivo proof-of-concept and target validation studies for multiple fibrosis projects. She joined Indalo Therapeutics in 2018 as the Executive Director of Pharmacology and developed novel integrin antagonists for fibrotic diseases until Indalo’s closure during the pandemic. Caralee then joined Xyphos Inc. (an Astellas company) in 2020 as the Director of Preclinical Development where she is currently developing novel CAR-T cell therapies for cancer.